Altaire Pharmaceuticals, Inc.March 9, 2017

FDA 483 - Altaire Pharmaceuticals, Inc. - March 09, 2017

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Altaire Pharmaceuticals, Inc.

Record Details

An FDA inspection of Altaire Pharmaceuticals, Inc., a sterile ophthalmic manufacturer in Aquebogue, NY, revealed significant deficiencies across multiple areas. Observations included failures in aseptic manufacturing procedures, incomplete laboratory records, inadequate laboratory controls for microbial testing and environmental monitoring, and a lack of validated manufacturing processes. Additionally, the firm's complaint handling procedures were found to be deficient, lacking proper review and trending analysis.

Company: Altaire Pharmaceuticals, Inc.
Inspection Date: March 9, 2017
Product Type: Drugs
Office: Division of Human and Animal Food Operations - East I
Person: Robert C. Horan (Biotechnology Specialist at FDA)

Open in Dashboard

ID · 6f5a38e3-831e-43d0-8235-9fde10683ff0